Ownership Search
Submit

Ownership Search

Quick way to search for ownership's filings

COGNITION THERAPEUTICS INC

Date Filed : Oct 15, 2021

Click here be alerted whenever COGNITION THERAPEUTICS INC [CGTX] files 4

SEC FORM 4SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
BIOS Memory SPV I, LP

(Last)(First)(Middle)
C/O BIOS PARTNERS,
1751 RIVER RUN, SUITE 400,

(Street)
FORT WORTHTX76107

(City)(State)(Zip)
2. Issuer Name and Ticker or Trading Symbol
COGNITION THERAPEUTICS INC [ CGTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/13/2021
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock10/13/2021C1,424,014A(1)1,424,014D
Common Stock10/13/2021C418,926A(1)418,926IBy Bios Fund I, LP.
Common Stock10/13/2021C245,029A(1)245,029IBy Bios Fund I, QP, LP.
Common Stock10/13/2021C78,298A(2)78,298IBy Bios Fund II, LP.
Common Stock10/13/2021C255,765A(2)255,765IBy Bios Fund II, QP, LP.
Common Stock10/13/2021C34,238A(2)34,238IBy Bios Fund II, NT, LP.
Common Stock10/13/2021P23,341A$1257,579IBy Bios Fund II, NT, LP.
Common Stock10/13/2021C351,844A(2)351,844IBy Bios Memory SPV II, LP.
Common Stock10/13/2021X33,495A$0.032385,339IBy Bios Memory SPV II, LP.
Common Stock10/13/2021S(3)90.28D$12385,248IBy Bios Memory SPV II, LP.
Common Stock10/13/2021C41,620A(2)41,620IBy Bios Fund III, LP.
Common Stock10/13/2021C24,263A(5)65,883IBy Bios Fund III, LP.
Common Stock10/13/2021P22,129A$1288,012IBy Bios Fund III, LP.
Common Stock10/13/2021C596,899A(2)596,899IBy Bios Fund III, QP, LP.
Common Stock10/13/2021C158,476A(5)755,375IBy Bios Fund III, QP, LP.
Common Stock10/13/2021P144,530A$12899,905IBy Bios Fund III, QP, LP.
Common Stock10/13/2021C34,472A(2)34,472IBy Bios Fund III, NT, LP.
Common Stock10/13/2021C25,593A(5)60,065IBy Bios Fund III, NT, LP.
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Series B Convertible Preferred Stock(1)10/13/2021C4,605,985 (1) (1)Common Stock1,424,014$00D
Series B Convertible Preferred Stock(1)10/13/2021C1,355,017 (1) (1)Common Stock418,926$00IBy Bios Fund I, LP.
Series B Convertible Preferred Stock(1)10/13/2021C792,547 (1) (1)Common Stock245,029$00IBy Bios Fund I, QP, LP.
Series B-1 Convertible Preferred Stock(2)10/13/2021C253,256 (2) (2)Common Stock78,298$00IBy Bios Fund II, LP.
Series B-1 Convertible Preferred Stock(2)10/13/2021C827,275 (2) (2)Common Stock255,765$00IBy Bios Fund II, QP, LP.
Series B-1 Convertible Preferred Stock(2)10/13/2021C1,138,040 (2) (2)Common Stock351,844$00IBy Bios Memory SPV II, LP.
Series B-1 Convertible Preferred Stock(2)10/13/2021C110,744 (2) (2)Common Stock34,238$00IBy Bios Fund II, NT, LP.
Series B-1 Convertible Preferred Stock(2)10/13/2021C134,626 (2) (2)Common Stock41,620$00IBy Bios Fund III, LP.
Series B-1 Convertible Preferred Stock(2)10/13/2021C1,930,673 (2) (2)Common Stock596,899$00IBy Bios Fund III, QP, LP.
Series B-1 Convertible Preferred Stock(2)10/13/2021C111,504 (2) (2)Common Stock34,472$00IBy Bios Fund III, NT, LP.
Warrant (right to buy)$0.03210/13/2021X33,49503/15/2016(4)03/15/2023(4)Common Stock33,495$00IBy Bios Memory SPV II, LP.
Simple Agreement for Future Equity(5)10/13/2021C24,263 (5) (5)Common Stock$232,933.33$00IBy Bios Fund III, LP.
Simple Agreement for Future Equity(5)10/13/2021C158,476 (5) (5)Common Stock$1,521,373.34$00IBy Bios Fund III, QP, LP.
Simple Agreement for Future Equity(5)10/13/2021C25,593 (5) (5)Common Stock$245,693.33$00IBy Bios Fund III, NT, LP.
Explanation of Responses:
1. The Series B Convertible Preferred Stock converted into Cognition Therapeutics, Inc. ("CGTX") common stock upon the closing of the issuer's initial public offering ("IPO"), as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration.
2. The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration.
3. On October 13, 2021, the reporting person exercised a warrant to purchase 33,495 shares of CGTX common stock for $0.032 per share. The reporting person paid the exercise price on a cashless basis, resulting in CGTX's withholding of 90.28 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 33,404 shares. The issuer paid cash to the reporting person in lieu of any fractional share amounts.
4. The warrant expires on the earliest of (i) March 15, 2023, (ii) upon a liquidation, dissolution or winding up of the Company, (iii) the closing of a Sale Transaction (as defined in the warrant), (iv) upon the closing of the issuer's IPO or (v) upon repayment of a promissory note issued in connection with the warrant.
5. The Simple Agreement for Future Equity converted into CGTX common stock upon the closing of the issuer's IPO at 80% of the per share offering price of the IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration.
By: /s/ Aaron G. L. Fletcher, Ph.D., Authorized Representative10/15/2021
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Stock View